Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587509 | 1.00 | RPS6KB1 (0.43) | RPS6KB1DPP4SIGMAR1 | |
| SCHEMBL3591894 | 1.00 | RPS6KB1 (0.43) | RPS6KB1DPP4SIGMAR1 | |
| SCHEMBL1413599 | 0.89 | SLC6A2 (0.45) | — | |
| SCHEMBL1239995 | 0.86 | RPS6KB1 (0.48) | RPS6KB1 | |
| SCHEMBL2675532 | 0.86 | RPS6KB1 (0.48) | RPS6KB1 | |
| SCHEMBL12052174 | 0.86 | RPS6KB1 (0.48) | RPS6KB1 | |
| SCHEMBL8249942 | 0.82 | RPS6KB1 (0.46) | RPS6KB1DPP4 | |
| SCHEMBL1396044 | 0.82 | RPS6KB1 (0.46) | RPS6KB1DPP4 | |
| SCHEMBL12052190 | 0.82 | RPS6KB1 (0.46) | RPS6KB1DPP4 | |
| SCHEMBL2790915 | 0.82 | RPS6KB1 (0.46) | RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069417-A1 | NOVEL PHENYL(4-PHENYLPYRIMIDIN-2-YL)AMINE DERIVATIVES, THEIR PREPARATION, AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069417-A1 | NOVEL PHENYL(4-PHENYLPYRIMIDIN-2-YL)AMINE DERIVATIVES, THEIR PREPARATION, AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS | IKBKB, NFKBIA, IKBKE | RPS6KB1 81/4885DPP4 1677/4885SIGMAR1 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.